Health knowledge made personal
WellPage for Gnrh
+ Bookmark › Share
Email Digg del.icio.us Reddit icon StumbleUpon Technorati
Go
Search posts:

Gnrh - Articles

FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonis by FDA Posted Tue 19 Oct 2010 2:13pm Safety Announcement [10-20-2010] The U.S. Food and Drug Administration (FDA) has notified the manufacturers of the Gonadotropin-Releasing Hormone (GnRH) agonists of the need... diseases (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer. FDA’s notification to manufacturers of GnRH agonists Read on »
GnRH Agonists: Label Change - Increased Risk of Diabetes and Cardiovascular Disease (Update) by FDA Posted Wed 20 Oct 2010 12:30pm   [Posted 10/20/2010]   AUDIENCE: Oncology, Endocrine, Cardiovascular   ISSUE: Gonadotropin-Releasing Hormone (GnRH) agonists will have new... (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer.   BACKGROUND: GnRH agonists are approved to treat Read on »
FDA formalizes warning of cardivascular risks for LHRH agonists by Dr. Arnon Krongrad Medical Doctor Posted Thu 21 Oct 2010 12:00am as luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists to include warnings about risk for cardiovascular disease and diabetes in product labeling for these drugs. The LHRH agonists are extensively used in management of prostate cancer, most commonly in men receiving radiation therapy for localized or locally advanced disease Read on »
US FDA reviewing the safety of LHRH agonists by Dr. Arnon Krongrad Medical Doctor Posted Mon 03 May 2010 12:00am ) agonists also known as gonadatropin releasing hormone or GnRH agonists is associated with metabolic side effects that include risks for cardiovascular disease and diabetes...: “Healthcare professionals should be aware of these potential safety issues and carefully weigh the benefits and risks of GnRH agonists when determining treatment.” “Patients Read on »
Are all LHRH agonists “just the same”? by Dr. Arnon Krongrad Medical Doctor Posted Sat 09 Oct 2010 12:00am releasing hormone or LHRH agonists (also often referred to as gonadatropin releasing hormone or GnRH agonists) also have “class effects” in that they all lower male testosterone..., it is reasonable to believe that different LHRH agonists may also have different effects in different patients but, as Vilar-González et al. have noted in a recent paper, there is almost Read on »
The luteinizing hormone releasing hormone (LHRH) by Dr. Arnon Krongrad Medical Doctor Posted Wed 17 Sep 2008 1:55pm Note: The terms “luteinizing hormone” (LH) and “gonadatropin” (Gn) are variously used by different authorities. Thus, LHRH and GnRH are also interchangeable terms in the medical literature. As far as The “New” Prostate Cancer InfoLink is aware, neither term is considered to be “absolutely correct.” We have chosen to use the terms LH and LHRH Read on »
Stress Not Healthly For Fertility by Emily Posted Mon 06 Jul 2009 8:05pm the production of gonadotropin releasing hormone ( GnRH ). GnRH stimulates the synthesis and secretion of the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH...) are increased and can directly inhibit GnRH. The study was performed on rats but the researchers believe it may also apply to all mammals. "We know stress affects the top-tier Read on »
Does switching LHRH agonists have a real clinical benefit? by Dr. Arnon Krongrad Medical Doctor Posted Mon 21 Feb 2011 12:00am There are two potentially good reasons for a patient who is receiving treatment with an LHRH agonist to switch from one product to another: the first is because he is having a problem with the adverse effects of his initial LHRH therapy; the second is because he has a rising PSA on the initial LHRH agonist. However, over the years Read on »
Delayed onset of castration resistance with serum T-based LHRH agonist regimens by Dr. Arnon Krongrad Medical Doctor Posted Fri 07 Jan 2011 12:00am A new paper just published online in Urology suggests that intermittent and testosterone (T)-based LHRH regimens are less likely to be associated with early onset... forms of LHRH agonist therapy and more complex forms of androgen deprivation therapy (ADT) based on LHRH agonist therapy might have beneficial long-term outcomes compared Read on »
The LHRH “flare” reaction: do we really know what we thought we knew? by Dr. Arnon Krongrad Medical Doctor Posted Wed 30 Dec 2009 12:00am While it has never been categorically proven that adding an oral antiandrogen like flutamide or bicalutamide (Casodex) to injections of LHRH agonists (e.g., leuprolide actetate) improves overall patient survival, there had been little doubt in people’s minds that giving an antiandrogen for a week or two before a first LHRH Read on »